RLMD

Over the past six months, Relmada Therapeutics' stock increased by 111.60% over the last 12 months, but experienced a year-to-date return of -20.70% and a 15.27% decrease in the past month as of September 26, 2026. Key events include a 40% surge on March 9, 2026, following positive 12-month interim clinical data for NDV-01 and a $160 million oversubscribed PIPE financing. In September 2026, the CEO and CFO purchased shares, leading to a rise, while the company also announced the exit of its Urology Chief Medical Officer. The stock price was down 11.8% in October 2026.